Cidara Therapeutics(CDTX) - 2023 Q4 - Annual Report

CD388 demonstrates prophylactic reduction of viral replication in the upper respiratory tract, or URT, and the incidence of PCR-confirmed influenza infection: The Phase 2a prophylactic efficacy results are based on 56 subjects enrolled in the trial, with 28 subjects receiving a single dose of CD388 (150 mg) and 28 subjects receiving a placebo. Cloudbreak Oncology Program and Our DFC Development Candidate CBO421 Statistical significance was pre-determined using a Wilcoxon rank-sum test with a one-sided type- ...